(1-methoxycyclobutyl)methanamine hydrochloride | 1443980-50-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-methoxycyclobutyl)methanamine hydrochloride
• 英文别名: (1-Methoxycyclobutyl)methanamine hydrochloride；(1-methoxycyclobutyl)methanamine;hydrochloride
• CAS: 1443980-50-4
• 化学式: C₆H₁₃NO*ClH
• mdl: MFCD24842884
• 分子量: 151.636
• InChiKey: QHQBSICDAMCQJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.16
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-chloro-N-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methylpyrido[3,4-d]pyrimidin-2-amine 、 (1-methoxycyclobutyl)methanamine hydrochloride 在 三乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 96.0h， 生成 N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-N8-((1-methoxycyclobutyl)methyl)-6-methylpyrido[3,4-d]pyrimidine-2,8-diamine
  参考文献：
  名称：

  [EN] N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  [FR] DÉRIVÉS DE N2-PHÉNYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE ET LEUR UTILISATION COMME INHIBITEURS DE MPS1

  摘要：

  本发明涉及式（I）的化合物，其中R1、R2、R3和R4均如本文所定义。本发明的化合物已知能够通过直接或间接与Mps1激酶本身相互作用来抑制单丝粒体1（Mps1，也称为TTK）激酶的纺锤体检查点功能。具体地，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。

  公开号：

  WO2015128676A1
• 作为产物：
  描述：

  1-羟基-环丁烷羧酸 在 ammonium hydroxide 、 硼烷四氢呋喃络合物 、 sodium hydride 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.0h， 生成 (1-methoxycyclobutyl)methanamine hydrochloride
  参考文献：
  名称：

  [EN] HETEROCYCLIC GLP-1 AGONISTS
  [FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1

  摘要：

  这项披露涉及到Formula (I)的GLP-1激动剂，包括其药用可接受的盐和溶剂化合物，以及包括这些化合物的药物组合物。

  公开号：

  WO2022028572A1

文献信息

• [EN] 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE<br/>[FR] DÉRIVÉS D'ACIDE 4-(2-FLUORO-4-MÉTHOXY-5-3-(((1-MÉTHYLCYCLOBUTYLE)MÉTHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL) CARBAMOYL)PHÉNOXY)-1-MÉTHYLCYCLOHEXANE-1-CARBOXYLIQUE ET COMPOSÉS SIMILAIRES COMME MODULATEURS DE RXFP1 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：ASTRAZENECA AB

  公开号：WO2022122773A1

  公开（公告）日：2022-06-16

  The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The present invention also relates to crystalline forms of such compounds. An exemplary compound is e.g. (A).

  本发明涉及4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基)双环[2.2.1]庚烷-2-基)氨基苯氧基)-1-甲基环己烷-1-羧酸衍生物及类似化合物，其为RXFP1调节剂，用于治疗心力衰竭、保留射血分数的心力衰竭、中等射血分数的心力衰竭、降低射血分数的心力衰竭、慢性肾脏病和急性肾损伤。本发明还涉及这种化合物的晶体形式。一个示例化合物是例如(A)。
• N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
  申请人：Cancer Research Technology Limited

  公开号：US10399974B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式 I 的化合物： 其中 R1、R2、R3 和 R4 均如本文所定义。已知本发明的化合物可直接或间接通过与 Mps1 激酶本身的相互作用抑制 Monospindle 1（Mps1--又称 TTK）激酶的纺锤体检查点功能。特别是，本发明涉及将这些化合物用作治疗和/或预防癌症等增殖性疾病的治疗剂。本发明还涉及这些化合物的制备工艺以及包含这些化合物的药物组合物。
• N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  申请人：Cancer Research Technology Ltd

  公开号：EP3110816B1

  公开（公告）日：2019-06-19
• N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20160362409A1

  公开（公告）日：2016-12-15

  The present invention relates to compounds of formula I: wherein R 1 , R 2 , R 3 and R 4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
• N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  申请人：Cancer Research Technology Limited

  公开号：US20180194761A1

  公开（公告）日：2018-07-12

  The present invention relates to compounds of formula I: wherein R 1 , R 2 , R 3 and R 4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.